anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Expose Contradiction

Slide function collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 14,162
Current window 10,351-10,380
Pages 473
Rows per page 30
Slide function: Expose Contradictionclear collectionreset all
18 30 60

Slide function

10,351-10,380 of 14,162

filter-aware
356
The slide uses a Q&A transcript format to highlight low adoption rates and physician skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
357
The slide uses a 'villain' narrative by framing a specific researcher (Jennifer Miller) and patient families as a 'cult' driving artificial demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
358
The slide uses a Q&A format to highlight skepticism among medical professionals regarding a drug's marketing presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
359
The slide uses direct quotes to undermine the credibility of the company's sales representatives and the drug's market reception.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
360
The slide uses a summary headline followed by a verbatim quote with key phrases highlighted in yellow.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
361
The slide uses direct quotes from a pediatric endocrinologist to undermine the viability of a drug (Vykat/diazoxide).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
362
The slide uses direct quotes from a pediatric endocrinologist to highlight concerns about the clinical management of diabetes risk associated with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
363
The slide highlights a discrepancy between the company's sales pitch and clinical best practices as perceived by an expert.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
364
The slide uses verbatim quotes from a consultation call to highlight a discrepancy between the company's risk management (handouts) and the physician's expectations of transient vs. permanent side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
365
The slide uses direct quotes from an endocrinologist to undermine the product's differentiation and pricing justification.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
366
The slide uses direct quotes to highlight a potential discrepancy between marketing claims and clinical reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
367
The slide highlights a direct contradiction between the company's marketing (Vykat) and expert clinical opinion.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
369
The slide highlights the endocrinologist's reluctance to prescribe the drug, noting that patient pressure was a primary driver for his involvement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
370
The slide uses a Q&A format to expose that the drug's popularity is manufactured by advocacy groups rather than medical demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
371
The slide uses a Q&A transcript format to expose potential conflicts of interest between a company (Soleno) and a patient association.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
372
The slide uses a Q&A transcript format to highlight potential misinformation or manipulation by study investigators regarding drug efficacy timelines.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
373
The slide uses direct quotes to frame the expert's skepticism and clinical concerns about the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
374
The slide uses a Q&A transcript format to expose potential flaws in clinical trial methodology and physician sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
376
The slide uses Q&A transcripts to undermine the value proposition of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
377
The slide uses a Q&A format to expose a gap in the company's support infrastructure.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
378
The slide uses a 'before-after' narrative structure to expose the contradiction between the physician's initial interest and his clinical assessment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
379
The slide uses a direct quote from a pediatric endocrinologist to undermine the drug's clinical value.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
380
The slide uses direct quotes to expose the contradiction between the physician's knowledge of drug inefficacy and their continued prescription behavior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
381
The slide uses direct quotes from an expert consultation to contrast grassroots patient enthusiasm with professional indifference.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
384
The slide uses a pull-quote style to highlight the expert's hesitation and lack of full support.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
385
The slide highlights a potential safety concern raised by an expert, specifically regarding pre-diabetic and obese patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
386
The slide presents a Q&A format where the expert questions the company's motives and the clinical rationale for their product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
387
The slide uses Q&A transcripts to undermine the credibility of the company's marketing claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
389
The slide uses a Q&A format to highlight expert skepticism regarding the drug's necessity and cost-effectiveness.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
390
The slide highlights a negative expert opinion on a drug being repurposed for PWS.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit